Cargando…
Safety and Efficacy of Rivaroxaban When Added to Aspirin Monotherapy Among Stabilized Post‐Acute Coronary Syndrome Patients: A Pooled Analysis Study of ATLAS ACS‐TIMI 46 and ATLAS ACS 2‐TIMI 51
BACKGROUND: A residual risk of ischemic events following an acute coronary syndrome (ACS) remains despite antiplatelet therapy. The addition of an antithrombin as part of a “dual pathway” approach may further improve outcomes as thrombin generation persists for several months post‐ACS. The present s...
Autores principales: | Gibson, William J., Gibson, C. Michael, Yee, Megan K., Korjian, Serge, Daaboul, Yazan, Plotnikov, Alexei N., Burton, Paul, Braunwald, Eugene |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6474929/ http://dx.doi.org/10.1161/JAHA.118.009451 |
Ejemplares similares
-
The “Dual-Pathway” Strategy after Acute Coronary Syndrome: Rivaroxaban and Antiplatelet Agents in the ATLAS ACS 2-TIMI 51 Trial
por: Cohen, Marc, et al.
Publicado: (2014) -
Dynamic TIMI Risk Score for STEMI
por: Amin, Sameer T., et al.
Publicado: (2013) -
Does Simplicity Compromise Accuracy in ACS Risk Prediction? A Retrospective Analysis of the TIMI and GRACE Risk Scores
por: Aragam, Krishna G., et al.
Publicado: (2009) -
Importance of the TIMI frame count: implications for future trials
por: Appleby, Mark A, et al.
Publicado: (2000) -
SAVOR-TIMI to DECLARE-TIMI: A Review on Cardiovascular Outcome Trials of Incretin-modulators and Gliflozins
por: Singh, Awadhesh K., et al.
Publicado: (2019)